Sandoz Inc. v. Amgen Inc.

Sandoz Inc. v. Amgen Inc.
Supreme Court of the United States
Decided June 12, 2017
Full case name	Sandoz Inc. v. Amgen Inc.
Docket no.	15-1039
Citations	582 U.S. 1 ( more )
Holding
Section 262(l)(2)(A) of the Biologics Price Competition and Innovation Act of 2009 is not enforceable by injunction under federal law. An applicant may provide notice under Section 262(l)(8)(A) prior to obtaining licensure.
Court membership
Chief Justice John Roberts Associate Justices Anthony Kennedy  · Clarence Thomas Ruth Bader Ginsburg  · Stephen Breyer Samuel Alito  · Sonia Sotomayor Elena Kagan  · Neil Gorsuch
Case opinion
Majority	Thomas, joined by unanimous
Laws applied
Biologics Price Competition and Innovation Act of 2009

Sandoz Inc. v. Amgen Inc., 582 U.S. 1(2017), was a United States Supreme Court case in which the court held that Section 262(l)(2)(A) of the Biologics Price Competition and Innovation Act of 2009 is not enforceable by injunction under federal law. An applicant may provide notice under Section 262(l)(8)(A) prior to obtaining licensure. ^{[1] [2]}

References

1. Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017).
2. Duffy, John (June 13, 2017). "Opinion analysis: The Supreme Court reverses another Federal Circuit patent case". SCOTUSblog. Retrieved July 16, 2025.

External links

• Text of Sandoz Inc. v. Amgen Inc., 582 U.S. 1(2017) is available from: Cornell Findlaw Justia

This article incorporates written opinion of a United States federal court. As a work of the U.S. federal government, the text is in the public domain .